Zydus announces licensing deal with Takeda for new GERD drug Vault

Quick Summary:

Factors contributing to GERD include age, body mass index (BMI), diet, tea/coffee intake, tobacco, and alcohol consumption.

The agreement allows Mankind Pharma to launch the drug for treating GERD under its trademark.

Yesterday it was announced that Mankind Pharma has entered into a non-exclusive patent licensing agreement with Takeda for commercialising Vonoprazan in the Indian market.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: India

Topics: Healthcare therapies. GERD Reflux esophagitis Pantoprazole Takeda Pharmaceutical Company Acid-related disorders Acid peptic disorders Mankind Pharma Vonoprazan Zydus Lifesciences Sharvil Patel Licensing agreement Gastrointestinal drug Vault

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-07-17 @ 18:59:26 (6 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 337 words

Reading Time: 2 minutes read

Sentences: 15 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 21664926

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 242 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions